In Silico Study of Novel Ketorolac as selective Cyclooxygenase-2 (COX-2)

  • Tanaya Jati Dharma Dewi Universitas Islam Negeri Maulana Malik Ibrahim


Ketorolac is a non-selective non-steroidal anti-inflammatory drug (NSAID). Ketorolac works by inhibiting the enzymes Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2(COX-2). Because it also interacts with it, it gives several side effects, especially on digestion. This study aimed to design and obtain a novel ketorolac, a modification of the ketorolac compound that is selective and does not interact with it. Modify the structure by adding a substituent at the para position in the benzene ring. The method was carried out in silico with molecular docking. Predictions were made from the physicochemical properties, ADME as a pharmacokinetic profile, and its toxicity using pkCSM and Protox online. The results showed that compound J had a better affinity than ketorolac for the Cyclooxygenase-2(COX-2) receptor and had no affinity for the Cyclooxygenase-1 (COX-1) receptor because it showed a positive docking score. Still, on the other hand, it showed different results. lack of adherence to Lipinski's 5th law as a physicochemical basis and provides predictions of hepatotoxicity

Author Biography

Tanaya Jati Dharma Dewi, Universitas Islam Negeri Maulana Malik Ibrahim

Department of Pharmacy, Faculty of Medicine and Health Science,Universitas Islam Negeri Maulana Malik Ibrahim Malang, Malang, Indonesia


Andy, H., Santoso, S.B. and Supraptomo, R.T.H. (no date) ‘Perbandingan Efektivitas Kombinasi Fentanyl – Paracetamol dan Fentanyl – Ketorolac terhadap Numerical Rating Scale ( NRS ) Post Operasi Seksio Sesarea The Comparison of the Effectiveness of Combination Fentanyl-Paracetamol with Fentanyl – Ketorolac on Numerical Rating Scale ( NRS ) Post Caesarean Section’, 005, pp. 80–88.
Banerjee, P. et al. (2018) ‘ProTox-II: A webserver for the prediction of toxicity of chemicals’, Nucleic Acids Research, 46(W1), pp. W257–W263. Available at:
Desmedt, C. et al. (2018) ‘Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient ’ s Body Mass Index’, 110, pp. 1115–1122. Available at:
Jain, A.N. and Nicholls, Æ.A. (2008) ‘Recommendations for evaluation of computational methods’, (February), pp. 133–139. Available at:
Katsila, T. et al. (2016) ‘Computational approaches in target identification and drug discovery’, Computational and Structural Biotechnology Journal, 14, pp. 177–184. Available at:
Kesuma, D. et al. (2018) ‘Uji in silico Aktivitas Sitotoksik dan Toksisitas Senyawa Turunan N-(Benzoil)-N’- feniltiourea Sebagai Calon Obat Antikanker’, JPSCR : Journal of Pharmaceutical Science and Clinical Research, 3(1), p. 1. Available at:
Łanocha-Arendarczyk, N. et al. (2018) ‘Expression and activity of COX-1 and COX-2 in acanthamoeba sp.-infected lungs according to the host immunological status’, International Journal of Molecular Sciences, 19(1), pp. 1–17. Available at:
Nørregaard, R., Kwon, T.H. and Frøkiær, J. (2015) ‘Physiology and pathophysiology of cyclooxygenase-2 and prostaglandin E2 in the kidney’, Kidney Research and Clinical Practice, 34(4), pp. 194–200. Available at:
Pires, D.E.V., Blundell, T.L. and Ascher, D.B. (2015) ‘pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures’, Journal of Medicinal Chemistry, 58(9), pp. 4066–4072. Available at:
Zahra, A.P. and Carolia, N. (2017) ‘Obat Anti-inflamasi Non-steroid ( OAINS ): Gastroprotektif vs Kardiotoksik’, Majority, 6, pp. 153–158.
How to Cite
DEWI, Tanaya Jati Dharma. In Silico Study of Novel Ketorolac as selective Cyclooxygenase-2 (COX-2). Proceeding Annual Symposium on Hajj and Umrah Medicine, [S.l.], v. 1, p. 93-107, dec. 2022. ISSN 2987-548X. Available at: <>. Date accessed: 26 may 2024. doi: